Guido Guidi

Guido Guidi has 35 years of experience in the pharmaceutical industry. He received his medical training at the University of Milan, where he obtained his MD in 1979. He continued his specialized training in Immunology and Allergology, as well as in Rheumatology in Milan until 1989. In parallel, he served as a medical advisor for Smith Kline and Roussel UCLAF and was medical director at Sharper Italia (Roussel UCLAF Group) from 1986 to 1989.

Dr. Guidi was previously Head of Pharma Europe and Head of Oncology Europe at Novartis, where he was responsible for bringing various drugs from clinical development to market including Cosentryx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Sandostatin, Femara, Glivec, and Jiakavi. While at Novartis, Guido originated and chaired the first edition of Bioupper, the Novartis accelerator for early-stage projects in Italy. He was also Chairman of the Novartis European Executive Committee and a member of the Innovation Management Board responsible for the Pharma division’s R&D program. He has also held different medical positions within Novartis, Sandoz, Roussel-UCLAF, and GSK. Guido is currently Chairman, Co-Founder, and Managing Partner of the technology transfer company AurorA-TT.